Shin Nippon Biomedical Laboratories Ltd  

(Public, TYO:2395)   Watch this stock  
Find more results for 2395
+1.00 (0.12%)
Apr 24 - Close
TYO data delayed by 20 mins - Disclaimer
Currency in JPY
Range 798.00 - 806.00
52 week 658.00 - 1,015.00
Open 801.00
Vol. 65,600.00
Mkt cap 32.10B
P/E     -
Div/yield     -
EPS -10.48
Shares 39.78M
Beta     -
Inst. own     -
Jun 26, 2015
Shin Nippon Biomedical Laboratories Ltd Annual Shareholders Meeting (Estimated) - 10:00AM GMT+9 - Add to calendar
May 8, 2015
Full Year 2015 Shin Nippon Biomedical Laboratories Ltd Earnings Release (Estimated) Add to calendar
Feb 13, 2015
Q3 2015 Shin Nippon Biomedical Laboratories Ltd Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 0.00% -4.50%
Operating margin -1.26% -4.58%
EBITD margin - 3.51%
Return on average assets 0.00% -2.09%
Return on average equity -0.14% -11.48%
Employees 1,866 -
CDP Score - -


12F, St.Luke's Tower, 8-1, Akashi-cho
CHUO-KU, TKY 104-0044
+81-3-55655001 (Phone)
+81-3-55656160 (Fax)

Website links


SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Officers and directors

Ryoichi Nagata President, Chief Senior Director of Sales, Chairman of Subsidiary, Representative Director
Age: 56
Shinji Nitanda Executive Officer, Chief Director of Finance and Accounting
Age: 44
Takeshi Yamakawa Chief Executive Officer of Subsidiary, Director
Age: 49
Toshihiko Seki Vice President, Deputy Chief Senior Director of Sales, Representative Director
Age: 58
Koichiro Fukuzaki Senior Managing Director, Chief Executive Officer of Subsidiary
Age: 55
Ken Takanashi Senior Managing Director
Age: 49
Shuichi Kanazashi Managing Director, President of TR Business Company
Hidenobu Sameshima Managing Director, Director of Safety Research Institute
Age: 58
Kazumi Uchi Executive Director
Age: 58
Hideshi Tsusaki Senior Director of Global Sales Unit, Director
Age: 47